Clinical Trials - Medika Life

Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack

INOVIO’s COVID-19 Vaccine Shows Durable Antibody and T Cell Responses

Medika Life - August 8, 2020

INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

SCOPE Summit is Expected to be a Major Platform for News in Clinical Trial Innovation

Why Healing Still Begins with Relationship

AI is Transforming Health Delivery: A Five-Year Reflection

Forget Hype – Digital Therapeutic Data Show the Category Can be Held to High Clinical Standards

LATEST

TRENDING

Health Possibilities We Can’t Afford to Block

AI is Transforming Health Delivery: A Five-Year Reflection

Texas: Endometriosis Clinical Study Participants – Women’s Health

Texas: Migraine Clinical Study Participants – Men and Women

Four Ways COVID has Changed Health Tech

Tech Marches On, While Humanity Drags Its Feet

Covid’s Elephant in the Room. We Must Address it

Doctors Find Drug for Lethal Lung Disease After Decades of Trying

It’s Time for New Tools to Overcome Smoking

Texas: Hot Flashes Clinical Study Participants – Women’s Health

EDITORS CHOICE

Four Ways COVID has Changed Health Tech

Texas: Pediatric Migraine Clinical Study Participants – Children

Colchicine Shows 48% Reduction in Future Cardio Issues for Heart Attack Victims

INOVIO’s COVID-19 Vaccine Shows Durable Antibody and T Cell Responses

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories